SFJ Pharmaceuticals, Inc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From SFJ Pharmaceuticals, Inc
Public Company Edition: PTC will get $350m up front as part of an initial $500m commitment. Also, while Biohaven and Vaxcyte launched traditional follow-on offerings, Recursion and Agios took the private placement and royalty sale routes, while others revealed job cuts and other strategic updates.
California biotech also notes prior licensing deal with Gilead for mitochondrial candidate. Twentyeight-Seven acquires RNA-splicing cancer candidate from Basilea.
Public Company Edition: Direct Biologics, YishengBio and Estrella Biopharma will go public by merging with special purpose acquisition corporations. Also, Vir lands a government contract worth up to $1bn, Idorsia raises CHF164m ($167.4m) in a real estate deal and Adamis reviews alternatives.
Deals show large investors’ appetite for early-stage biotech, but can VC and PE rub along?
- Specialty Pharmaceuticals